| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CST9 |
| Uniprot No | Q5W186 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-159aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMWCSEEEMGGNNKIVQDPMFLATVEFALNT FNVQSKEEHAYRLLRVLS SWREDSMDRKWRGKMVFSMNLQLRQTVCRK FEDDIDNCPFQESLELNNVRQGISFPQVHSCGCCMGCGVGTGAAD KAI PRDKGK |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CST9重组蛋白的参考文献示例(注：部分文献为假设性概括，实际研究中请根据具体需求检索最新文献)：
---
1. **标题**：*Expression and Functional Characterization of Recombinant Human Cystatin 9 in E. coli*
**作者**：Zhang Y, Wang L, et al.
**摘要**：本研究成功在大肠杆菌中表达并纯化了重组人CST9蛋白，通过酶活性抑制实验证实其能有效抑制组织蛋白酶B的活性，为研究CST9在肿瘤中的生物学功能提供了工具。
2. **标题**：*Recombinant CST9 Suppresses Tumor Cell Invasion via MMP-9 Regulation*
**作者**：Lee S, Kim J, et al.
**摘要**：利用重组CST9蛋白处理乳腺癌细胞，发现其通过下调基质金属蛋白酶MMP-9的表达，显著抑制癌细胞迁移和侵袭，提示CST9可能作为潜在的肿瘤治疗靶点。
3. **标题**：*Structural Insights into Cystatin 9 by X-ray Crystallography*
**作者**：Smith R, Brown T, et al.
**摘要**：通过X射线晶体学解析了重组CST9蛋白的三维结构，揭示了其与半胱氨酸蛋白酶结合的活性位点，为设计基于CST9的抑制剂奠定结构基础。
4. **标题**：*Recombinant CST9 Attenuates Inflammation in Murine Sepsis Models*
**作者**：Gupta A, Patel K, et al.
**摘要**：在小鼠脓毒症模型中，重组CST9蛋白通过抑制过度激活的蛋白酶活性，显著减轻炎症反应和器官损伤，表明其具有治疗炎症性疾病的潜力。
---
建议通过PubMed或Web of Science检索关键词“CST9 recombinant”“Cystatin 9 expression”以获取真实文献。
**Background of CST9 Recombinant Protein**
Cystatin 9 (CST9), a member of the cystatin superfamily, is a cysteine protease inhibitor that regulates proteolytic enzymes involved in various physiological and pathological processes. The cystatin family, characterized by conserved structural motifs, plays critical roles in modulating cysteine cathepsins, enzymes implicated in protein degradation, immune response, and cellular homeostasis. CST9 is distinguished by its tissue-specific expression, particularly in epithelial and immune cells, suggesting specialized functions in barrier defense and inflammation control.
Recombinant CST9 protein is engineered using genetic engineering techniques, typically expressed in bacterial or mammalian systems to ensure proper folding and post-translational modifications. Its production enables detailed study of its biochemical properties, inhibitory activity, and interactions with target proteases. Research highlights CST9's involvement in cancer progression, neurodegenerative diseases, and microbial infections, where dysregulated protease activity contributes to pathogenesis. For instance, CST9 may suppress tumor invasion by inhibiting cathepsins that degrade extracellular matrices or modulate immune cell activity in chronic inflammation.
Therapeutic potential drives interest in recombinant CST9. including its application in drug development for conditions linked to excessive protease activity. Additionally, it serves as a tool for diagnostic assays, structural studies, and screening protease inhibitors. Challenges remain in optimizing its stability, delivery, and specificity in vivo. Ongoing studies aim to elucidate its full mechanistic spectrum and validate clinical relevance, positioning CST9 as a promising target for biomedical innovation.
×
